Summar3:
A radiobinding assay for the detection of autoantibodies against islet amyloid polypeptide was developed, analytically validated, and-in parallel with a similar assay for the detection of autoantibodies against insulin -applied to sera from recent-onset Type I (insulin-dependent) diabetic patients and from age-and sex-matched control subjects. There was no difference in islet amyloid polypeptide autoantibody titres between patient groups and matched control subjects, nor within subject groups according to age. At onset of Type 1 diabetes, elevated islet amyloid polypeptide-autoantibody levels ( > 97th percentile of control subjects) were only detected in 1 of 30 patients aged 0-19 years and in 2 of 35 patients aged 20-39 years. By contrast, insulin autoantibodies were frequently demonstrated, in particular at onset of diabetes under age 20 (0-19 years: 18 of 30 patients; 20-39 years: 10 of 35 patients; p < 0.01 vs matched control subjects). Islet amyloid polypeptide autoantibodies were not de, tectable in 3 insulinoma patients nor in 37 patients (aged 33-70 years) with Type 2 diabetes (vs i of 40 in matched control subjects). In positive serum, adsorption onto protein A-Sepharose removed islet amyloid polypeptide binding activity, hereby confirming its antibody nature. In conclusion, Type 1 diabetes is associated with an age-dependent autoantibody reaction against insulin but not against islet amyloid poly, peptide. Conditions associated with amyloid deposition in islets (Type 2 diabetes, insulinoma and ageing) do not favour the formation of autoantibodies against islet amytoid polypeptide.
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Clinical onset of Type 1 (insulin-dependent) diabetes mellitus is often accompanied by the presence of circulating IgG which bind to islet cell antigens [1, 2] . The diabetesspecificity of these autoantibodies and their appearance before clinically overt disease fuelled the concept of a relatively long pre-clinical stage, during which detection of autoimmune markers would allow prediction of the disease [3] [4] [5] [6] . So far, islet cell cytoplasmic antibodies (ICA) have been most commonly used in long-term follow-up studies of groups at risk for Type i diabetes [4] [5] [6] . They are consequently best characterized in terms of positive predictive value depending upon age of disease onset, antibody titre and persistence.
With the characterization of Beta-cell specific targets for circulating immunoglobulins [7] [8] [9] [10] , more quantitative immunoassays can be designed for large-scale evaluation. Antibodies against glutamate decarboxylase, insulin and proinsulin have been identified and their presence can complement information gained fl'om ICA testing. For example, simultaneous positivity for ICA and insulin autoantibodies (IAA) has been claimed to confer greater risk for subsequent development of Type i diabetes than positivity for either test alone [1] [2] [3] [11] [12] [13] [14] . No pathogenic role has so far been ascribed to these autoantibodies. Rather it is conceivable that they arise as a consequence of inappropriate Beta-cell specific antigen expression or presentation during autoimmune insulitis and cellular destruction. Various Beta-cell specific (secretory) peptides can thus be considered as candidate targets for diabetes-associated autoantibodies. In the search for new, perhaps complementary, immune markers of Type i diabetes, the present stud3, was designed to investigate whether the autoantibody response mounted against Beta cells might also involve islet amyloid polypeptide (IAPP) and if so, whether the occurrence of autoantibodies against this Beta-celt secretory peptide [15] [16] [17] parallels or complements that directed against the other secretion product, insulin. To this effect we have developed a radiobinding assay (RBA) for detection of IAPP autoantibodies (IAPP-AA) in human serum. In the specific case of IAA, RBA assays have been shown to surpass ELISA-technology in recognizing diabetes-associated autoantibodies [18] [19] [20] [21] [22] . Like other islet-cell specific auto- antibodies that precede or accompany clinical onset of Type i diabetes, IAA belong to the IgG-class. Diabetesassociated IAA display high affinity [22] . Clinical manifestations of autoimmune diseases are believed to be accompanied or preceded by transition from early IgM autoantibodies to IgG-autoantibodies and by affinity maturation [23] . Because high affinity autoantibodies are likely to be clinically more relevant and are most reliably detected by RBA, after validation of the latter methodology we selected it for IAPP-AA determination. In parallel with a similar RBA for IAA, the IAPP-AA assay was applied to sera from 65 patients at onset of Type 1 diabetes and from an equal number of age-and sex-matched control subjects. An additional goal of the study was to look for the possible occurrence of IAPP-AA in association with Type 2 diabetes or with other conditions such as insutinoma and ageing that are, albeit to variable degrees, characterized by a propensity to form amyloid deposits. This abnormalmaterial, mainly composed of IAPP [15] [16] [17] , could become antigenic in an older population with an overall increased tendency towards autoantibody formation [24, 25] .
Subjects and methods

Subjects
Sixty-six Type t diabetic patients (aged 0-39 years at clinical onset) were recruited through the Belgian Diabetes Registry, a data and sample bank for Type 1 diabetic patients and their first degree rela-tives [26] . Only patients from whom blood was sampled before or within 7 days after initial insulin treatment were enrolled. [27] . In Type 2 diabetic patients, disease duration ranged from i month up to 23 years (median duration 8 years).
One patient was treated with diet alone, while I0 patients were on oral hypoglycaemic drugs, nine on insulin therapy and the remainder on combination therapy. For each patient group an equal number of age-and sex-matched healthy control subjects was selected. This group included blood donors and healthy laboratory workers ( > 18 years old), as well as children (0-18 years) attending the participating clinical centres for minor surgery [25, 26] . Before the start of the study, it was agreed that the control subjects would not be informed of assay results and would not be submitted to any form of questioning or additional testing.
Assay of autoantibodies
Insulin autoantibodies (IAA) were determined by a radiobinding assay (RBA), according to a modification [28] of the method of Palmer [7, 29] . Briefly, human mono-lZsI-tyrosine-A14 insulin (theoretical specific activity: 360 gCi/gg) was prepared by chloramine T iodination and HPLC-purification of recombinant insulin (crystalline human insulin, Humulin; kindly donated by E. Lilly Corp., Indianapolis, Ind., USA) [30] . After removal of free and antibody-bound endogenous insulin by acid-charcoal extraction, supernatants were incubated with human 125I-insulin for 18 h at 4 °C (10-20 000 cpm/tube), and the amount of antibody-bound tracer was measured in the pellets formed by polyethylene glycol precipitation of immunoglobulins. For each sample, total tracer binding was corrected for non-specific binding (NSB) by subtracting the counts obtained raider identical conditions except for the presence of an excess of unlabelled insulin (10 -6 mol/1). Serum samples were run in duplicate. IAA-activity was expressed as 12sI-insulin-binding capacity according to the formula:
% tracer bound = mean cpm samples -mean q~m samples with excess unlabelled insulin mean cpm total counts (n = 5)
NSB generally amounted to 1% of total counts. Results were rejected and samples re-tested when duplicates differed by more than 10 %. The sensitivity of the assay was optimized by doubling the final concentration of bovine serum albumin (BSA, RIA grade; Sigma Chemical Co, St.Louis, Mo., USA; 10 g/l) and of bovine gamma globulin (BGG, 99% purity; Sigma, 5 g/l) in the assay mixture as compared to the original protocol of Palmer [7, 28, 29] . Over a 6-month period, between-assay coefficient of variation (CV) equalled 10.2%, 10.8 % and 30.0 %, respectively for internal quality control sera with IAA amounting to t2.7 %, 6.5 % (both IAA-positive) and 0.3 % (IAA-negative serum) of tracer bound. The assay was validated in the 1990 -Immunology of Diabetes Workshop (IDW) for IAA where it detected IAA in 12 of 30 (40%) patients with Type 1 diabetes, in 7 of 22 (32 %) first degree relatives of patients, in 5 of 8 (63 %) pre-diabetic subjects and 0 of 61 (0%) healthy control subjects.
The IAPP-AA-assay was also based on a radiobinding procedure. Mono human 125I-IAPP (theoretical specific activity: 550 gCi/gg) was prepared by iodination of human IAPP amide (Peninsula Laboratory, Inc., Belmont, Calif., USA) according to a modification of the chloramine T method [30] . Briefly, human IAPPamide (10 gg freshly dissolved in 10 gl 0.1 mol/1 NaH2PO4, 0.1% Triton X-100, pH 3.2) was first mixed with 25 gl 0.1 mol/1 phosphate buffer, 0.1% Triton X-100, pH 7.6, and 10 gl Na ~2sI (100 mCi/mt, IMS-30; Amersham Intern ational, Amersham, Bucks, UK). The reaction was initiated by pipetting 25 gl chloramine T (4.2 ]xg added in 25 ~ phosphate buffer, 0.1% Triton X-100, pH 7.6) and stopped 90 s later by addition of 25 gl NaaS2Os (0.4 mg/ml in 0.02 moi/1 phosphate buffer, 0.1% Triton X-100, pH 7.6). The oxidation reaction proceeded at 4 °C under gentle stirring. 12sI-IAPP was then purified by HPLC using a gBondapack C18 column and an acetonitrile gradient in ethanolamine buffer (pH 2.5). One single major peak eluted at 35 mI. Fractions of interest were pooled and mixed with an equal volume of 2 mol/1 acetic acid containing 2.5 g/l BSA and stored at 4 °C until use (Fig. 1 A) . In order to avoid polymerization, the tracer was never dried out and all assay solutions were supplemented with 0.1% Triton X-100. Serum samples to be assayed for IAPP-AA were not first treated by acid-charcoal because their IAPP concentration (2-6 pmol/1) [31] is so low that, according to the law of mass action, formation of IAPP-anti-IAPP immune complexes becomes negligible, even in the presence of very high affinity antibodies (K = 10 ~° l/too0 [32] . Furthermore, omission of the acid charcoal step avoids a four-fold dilution, thereby increasing assay sensitivity. Like for IAA, all samples were run in duplicate and data corrected for NSB, by a parallel assay of binding in the presence of an excess of unlabelled IAPP (5.10-7 mol/1 final). Typically, NSB averaged 1-2 % of total counts. Less than 10 % difference between duplicates was tolerated.
Islet cell cytoplasmic antibodies (ICA) were measured by means of an indirect immunofluorescence technique using cryosections of fresh-frozen human pancreas (blood group O) for substrate [33] . Results were expressed as Juvenile Diabetes Foundation (JDF) units. Sera with less than 6 JDF units were considered to be negative. The test was clinically validated through repeated participation in external quality control programmes [34] . Serum IgG were removed by applying 400 gl of serum diluted volume/volume in phosphate buffered saline, pH 8.0, onto a protein A-Sepharose mini-column (Pharmacia, LKB, Brussels, Belgium; 1.5 mg of powder swollen to 5 ml in phosphate buffered saline, pH 8.0) and eluting with phosphate buffered saline, pH 8.0. The absorbance of the eluate was monitored at 277 nm wavelength. The flowthrough fractions were collected and concentrated to the original volume in Centricon 30 filters (Amicon, Brussels, Belgium).
Statistical analysis
For IAPP-AA-titres the statistical significance of differences between experimental groups was assessed by a two-tailed MannWhitney U test. In case of multiple comparisons p-values were corrected (Pc) by means of Bonferroni-adjustments and statistical significance was defined as p or p~ < 0.05. For comparison of prevalences, the chi-square test was used. Figure 1 A shows the HPLC elution profile of radioactivity following iodination of human IAPE Fractions 71 to 74 were pooled and stored as described under methods until use in the RBA. After 5 weeks of storage, the tracer eluted at the same position in HPLC ( Fig. 1 B) ; its elution on Sephadex G50 columns also remained identical to that of freshly labelled rat IAPP, which is known not to polymerize [15] [16] [17] (data not shown).
Results
Analytical validation of a radiobinding (RBA)-assay for IAP P-autoantibody determination (IA P P-AA )
As illustrated in Figure 2 , the elaborated RBA was able to consistently detect IAPP-antibodies (expressed as % human mono 125I-IAPP specifically bound) in a hyperimmune rabbit anti-rat IAPP-amide serum. The magnitude of the IAPP-binding activity varied conversely to serum dilution (Fig. 2) , dropping from 62 % at 1:4000 to 3 % at 1 : 10 ~. Over a 3-month period, between-run imprecision of the assay was evaluated by cumulating results obtained in 15 different experiments for a normal control serum as well as for two different dilutions of hyperimmune rabbit anti-rat IAPP-amide serum in IAPP-AA-negative serum. Interassay CV (n = 15) amounted to 25.7 %, 12.6% and 11.7%, respectively for a level of specific tracer binding corresponding to 1.5 % (SD = 0.4 % ), 6.7 % (SD = 0.8 % ) and 13.8 % (SD = 1.6 % ). Figure 3 represents the distribution of IAPP-AA-titres obtained in the various populations studied. IAPP-binding activity was not significantly different between patients suffering from Type 1 or Type 2 diabetes and their age-and sex-matched control subjects, nor between different age groups of healthy control subjects (pc > 0.05). A small number of patients (5 of 102), but also of control subjects (4 of 102), displayed more than 2 % tracer binding. In two patients and one control subject, tracer binding was higher than 15 %. Varying the cutoff level for IAPP-AA-positivity between the 90th and 99th percentiles of matched control subjects did not lead to significant differences in IAPP-AA-prevalence in any of the patient groups studied (p~ > 0.05 with chi-square test). There was no association between IAPP-AA-positivity and presence of ICA or IAA in patients with Type 1 diabetes nor in control subjects. IAPP-AA were not detectable in three patients with insulinoma. Absorption of -90 % of serum IgG by protein A-Sepharose decreased the IAPP- The horizontal line segments represent the median value for each subject group, For each set of patients and matched control subjects, three dotted lines are drawn representing the 97th percentile (upper line), 95th percentile (middle line) and 90th percentile (lower line) for IAA-titres from the appropriate control group. Using the 97th or 99th percentile of matched control subjects for cutoff, IAA prevalence was significantly increased in Type i diabetic patients at 0-19 years (p < 0.001 vs matched control subjects with chi-square test), as well as in older patients at onset (p < 0.01 vs control subjects) AA or IAA titres by more than 70 % in strongly IAPP-AA-or IAA-positive human sera. This observation is taken as evidence that in both instances the high affinity peptide-binding activity measured by RBA is due to the presence of specific IgG. In marked contrast to the lack of association of IAPP-AA with clinical onset of Type I diabetes, ICA and IAA were frequently present in this patient group (Fig. 4) . As expected, ICA-positivity ( > 6 JDF units) was frequently noted in Type i diabetic patients ( (Fig. 3) .
Determination of lAPP-AA in patient sera: lack of association with disease and established markers
Discussion
A search for IAPP-AA in Type i diabetic patients can provide information complementary to that derived from currently assayed antibodies. Disease-specific occurrence of immunoglobulin binding to IAPP would indicate that autoantibody formation in Type 1 diabetes is not restricted to one secretory product of the pancreaticBeta cell, namely insulin, but includes a reactivity against other constituents of the Beta-cell secretory vesicle as already shown for carboxypeptidase H [37] . In view of the Beta-cell specificity of IAPP, IAPP-binding immunoglobulin could serve as a simple and quantitative marker for detection of Beta cell selective autoimmune reaction. In the present study, however, increased prevalence or titres of IAPP-AA were not detected at clinical onset of Type 1 diabetes. Although a transient presence of IAPP-AA during a preclinical phase of the disease may not be excluded, our negative finding raises the intriguing possibility of selectivity in antibody formation against certain Beta-cell specific peptides.
Although it is capable of measuring IAPP-binding immunoglobulin, our RBA detected only few patients with circulating IAPP-AA. No difference in IAPP-AA-prevaience was found between Type 1 diabetic patients (5%) and age=matched control subjects (3 %) whereas IAA occurred in 43 % of the Type 1 patients vs 3 % in control subjects. Using an ELISA-technique, Clark et al. [38] noticed a higher prevalence of IAPP-AA in Type 1 and Type 2 diabetic patients than in normal control subjects. These discrepant observations may have originated flom the use of different assay systems [20, 32, 39] . Whereas ELISA is to be considered as a capacity assay, the RBA-signal depends on both antibody concentration and affinity. When both techniques were applied to a series of insulin (auto)antibodies, no correlation between ELISA-and RBA-titres was found [t8]. Moreover, the two techniques are not always concordant in classifying samples as antibody-positive or negative. Positivity in ELISA only suggests the presence of high capacity low-affinity antibodies, whereas positivity in RBA merely indicates the occurrence of low-capacity high-affinity antibodies [32, 39] . Association of IAA with Type 1 diabetes has been demonstrated by RBA but not by ELISA [21] leading to the conclusion that RBA is superior to ELISA in detecting IAA in Type 1 diabetes at onset and in relatives at high risk for the disease [21, 22] . et al.: Autoantibodies against islet amyloid polypeptide in human serum Our negative findings cannot be attributed to inadequacy of the tracer. The prepared mono-125I-IAPP did not exhibit altered charge or hydrophobicity as judged by repeated HPLC chromatography over a 5-week period. It did not undergo polymerization during storage as indicated by gel filtration. Successive testing over a 3-month period illustrated its specific binding to a hyperimmune serum in a reproducible and dose-dependent manner. We consider it unlikely that IAPP-AA were technically undetectable as a result of complex formation with the circulating peptide, since plasma IAPP levels are extremely low. Of course it cannot be excluded that circulating IAPP-AA are directed towards an epitope containing the C-terminal tyrosine-amide making them unreactive with iodinated IAPE The significance of IAPP-AA of the IgG class in sera of a minority of patients and control subjects is unknown. Their lack of relationship with age, sex and disease would suggest that they are "natural" antibodies [40] rather than the consequence of an imbalance within the immune system resulting in a disruption of tolerance [41] .
It is at present not known why Type 1 diabetes would be associated with autoantibodies against one (insulin) and not another (IAPP) of the Beta-cell specific secretory products. Antigenicity of peptides is a complex matter depending upon parameters such as molecular weight, prevailing concentration and molecular mobility [42] [43] [44] . In this respect, it is interesting to note that proinsulin is reputed to be more immunogenic than insulin although the naturally formed antibodies are usually directed towards the insulin moiety or either one of the C-peptide-insulin junctions [39, 45] . The smaller size of IAPR its lower concentration in the Beta cell and in the systemic circulation, as well as its propensity to adopt the less mobile Betapleated sheet configuration [15] [16] [17] might all contribute to reducing the immunogenicity of IAPP relative to (pro)insulin.
IAPP-antibodies were not detected in conditions with extracellular accummulations of IAPP-polymers, such as in ageing, Type 2 diabetes and insulinoma. In these deposits, IAPP is no longer monomeric but polymerized so that antibodies, directed against a conformational epitope that is exclusively present in the polymer, will escape detection using a radiolabelled monomer of IAPR
In conclusion, an RBA for IAPP-AA was developed and validated. It detected high affinity IgG-IAPP-AA in a few patients with Type I and Type 2 diabetes, as well as in control subjects of various age groups. No preferential association of IAPP-AA with either type of diabetes or progressing age could be demonstrated. On the other hand, Type i diabetic patients presented a higher prevalence of insulin antibodies. Thus, in this disease, for reasons unknown, certain Beta-cell specific peptides appear not to trigger autoantibody production. 
